Merck KGaA (MKGAF) Stock Price, News & Analysis

Company Overview

Merck KGaA, operating under the OTCMKTS:MKGAF ticker, is a leading science and technology company headquartered in Darmstadt, Germany. Founded in 1668, the firm remains majority-owned by the founding Merck family and has grown from a small pharmacy into a global enterprise. Its activities span three core business sectors—Healthcare, Life Science and Performance Materials—serving customers in pharmaceuticals, biotechnology, electronics and specialty chemicals.

In its Healthcare division, Merck KGaA develops and markets prescription medicines in areas such as oncology, immuno-inflammation and fertility. The company’s research and development focus includes targeted cancer therapies, emerging immunotherapies and innovative treatment options for women’s health. Clinical studies are conducted at multiple sites worldwide, reflecting Merck KGaA’s commitment to advancing patient care and expanding its therapeutic pipeline.

The Life Science segment provides tools, consumables and services for biopharmaceutical research, diagnostics and production. Offerings include laboratory reagents, single-use technologies and bioprocess solutions designed to accelerate drug development and manufacturing. In parallel, the Performance Materials arm delivers high-tech solutions for semiconductor manufacturing, consumer electronics and surface treatment, supplying specialty chemicals, liquid crystals for displays and ultraviolet curable resins.

With operations in over 60 countries and production facilities on four continents, Merck KGaA combines a global footprint with a decentralized management structure. Under the leadership of Chief Executive Officer Belén Garijo and an executive board drawn from diverse scientific and commercial backgrounds, the company emphasizes sustainable growth, strategic partnerships and digital transformation. Its broad geographic reach and diversified portfolio position Merck KGaA as a prominent player in multiple high-growth industries.

Key Stats

• Today's Range: $125.37 to $131.31
• 50-Day Range: $124.46 to $143.50
• 52-Week Range: $118.05 to $200.56
• Volume: 822 shs
• Average Volume: 1,059 shs
• Market Capitalization: $16.20 billion
• P/E Ratio: 19.14
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Merck KGaA Stock Analysis - MarketRank™

Merck KGaA scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Merck KGaA.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 8.21%

Earnings Growth

Earnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck KGaA is 19.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck KGaA is 19.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.69.

Price to Book Value per Share Ratio

Merck KGaA has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of Merck KGaA has been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 122.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 6.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merck KGaA does not currently pay a dividend.

Dividend Growth

Merck KGaA does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.43% of the float of Merck KGaA has been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 122.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 6.47%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 1.00

News Sentiment

Merck KGaA has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Merck KGaA this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck KGaA insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.10% of the stock of Merck KGaA is held by institutions.

MKGAF Stock Analysis - Frequently Asked Questions

How have MKGAF shares performed this year?

Merck KGaA's stock was trading at $151.56 on January 1st, 2025. Since then, MKGAF shares have decreased by 17.3% and is now trading at $125.37.

How do I buy shares of Merck KGaA?

Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/14/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MKGAF
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 496151720
• Fax: 49-61-5172-2000
• Employees: 62,908
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $6.81
• Trailing P/E Ratio: 19.14
• Forward P/E Ratio: 12.86
• P/E Growth: N/A
• Net Income: $3.06 billion
• Net Margins: 12.60%
• Pretax Margin: 15.64%
• Return on Equity: 10.17%
• Return on Assets: 5.74%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 1.31
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $22.72 billion
• Price / Sales: 0.71
• Cash Flow: $37.76 per share
• Price / Cash Flow: 3.32
• Book Value: $212.00 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 129,240,000
• Free Float: N/A
• Market Cap: $16.20 billion
• Optionable: Not Optionable
• Beta: 0.96